Monitor for any future amendments that could signal a shift from passive to active intent, particularly if Commodore Capital engages with management or increases its stake significantly. The combined passive ownership by Commodore, ADAR1 Capital (17.2%), and Ikarian Capital creates a notable institutional base post-merger.
Price Chart
How similar events traded
Executive Summary
Commodore Capital LP filed a Schedule 13G disclosing a 5.6% passive stake in Mentari Therapeutics (formerly InMed Pharmaceuticals), representing 2,977,630 common shares as of November 6, 2026. This is a new position following the company's reverse merger with Mentari on November 6, 2026, and adds to existing passive ownership by ADAR1 Capital (17.2%) and Ikarian Capital.
Key Financial Metrics
Key Facts
- Commodore Capital LP disclosed a 5.6% passive stake in Mentari Therapeutics (formerly InMed Pharmaceuticals) as of November 6, 2026.
- The stake consists of 2,977,630 common shares, held via Commodore Capital Master LP.
- The filing certifies passive intent under Rule 13d-1(c), with no intent to influence control.
- Ownership percentage is based on 52,813,914 shares outstanding as of November 6, 2026, per the company's 8-K filed November 10, 2026.
- This is a new position following the reverse merger with Mentari Therapeutics completed on November 6, 2026.
Financial Impact
5.6% stake valued at approximately $504,000 based on $9M market cap.
Risk Factors
- Passive stake filing; no indication of activist intent or engagement.
- Small market cap ($9M) and low liquidity could amplify any future stake changes.
- Post-merger company (Mentari Therapeutics) has limited public trading history.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001831942-26-000046 |
| Document: 0001831942-26-000046-index-headers.html | 0001831942-26-000046 |
| Document: 0001831942-26-000046-index.html | 0001831942-26-000046 |
| Document: 0001831942-26-000046.txt | 0001831942-26-000046 |
Track record
10 reports on MTRI
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $17.90 Now $19.87 −11.01% settles Dec 15
- Nov 16, 2026today 8-K Neutral 6/10 Entry $18.60 Now $19.87 +6.83% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Viewing Entry $19.02 Now $19.87 +4.47% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $15.75 Now $19.87 +26.16% settles Dec 15
- Nov 12, 20264d ago SC 13D Neutral 5/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 10, 20266d ago 8-K Mixed 7/10 Entry $15.61 Now $19.87 +27.30% settles Dec 10
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers